Peter H. Jones

1.5k total citations · 2 hit papers
13 papers, 1.1k citations indexed

About

Peter H. Jones is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Peter H. Jones has authored 13 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 5 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Economics and Econometrics. Recurrent topics in Peter H. Jones's work include Lipoproteins and Cardiovascular Health (9 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Peter H. Jones is often cited by papers focused on Lipoproteins and Cardiovascular Health (9 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Peter H. Jones collaborates with scholars based in United States, Canada and Denmark. Peter H. Jones's co-authors include Terry A. Jacobson, Don P. Wilson, Carl E. Orringer, Marlys L. Koschinsky, Catherine J. McNeal, Børge G. Nordestgaard, Kevin C. Maki, Kamlesh M. Thakker, Radhika Nair and Harold Bays and has published in prestigious journals such as SHILAP Revista de lepidopterología, Arteriosclerosis Thrombosis and Vascular Biology and The American Journal of Cardiology.

In The Last Decade

Peter H. Jones

13 papers receiving 1.1k citations

Hit Papers

National Lipid Association recommendations for patient-ce... 2014 2026 2018 2022 2014 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary
    2014 364 citations Terry A. Jacobson, Matthew K. Ito et al. Journal of clinical lipidology profile →
  2. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
    2019 339 citations Don P. Wilson, Terry A. Jacobson et al. Journal of clinical lipidology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter H. Jones United States 9 780 349 302 220 174 13 1.1k
David Colquhoun Australia 11 631 0.8× 341 1.0× 341 1.1× 129 0.6× 143 0.8× 16 1.1k
J.J.P. Kastelein Netherlands 15 835 1.1× 427 1.2× 319 1.1× 178 0.8× 254 1.5× 30 1.2k
Antonio J. Vallejo‐Vaz Spain 19 877 1.1× 469 1.3× 369 1.2× 172 0.8× 282 1.6× 51 1.5k
David Neff United States 17 938 1.2× 394 1.1× 269 0.9× 299 1.4× 233 1.3× 39 1.4k
Michael Stepanavage United States 11 905 1.2× 540 1.5× 242 0.8× 167 0.8× 254 1.5× 16 1.3k
José Luis Zamorano Spain 5 994 1.3× 472 1.4× 468 1.5× 367 1.7× 187 1.1× 9 1.5k
Brad Bisson United States 7 1.3k 1.7× 675 1.9× 562 1.9× 164 0.7× 229 1.3× 9 1.8k
Anja Vogt Germany 19 1.1k 1.4× 353 1.0× 397 1.3× 296 1.3× 234 1.3× 66 1.5k
Greg Brown United States 3 1.3k 1.7× 755 2.2× 573 1.9× 162 0.7× 264 1.5× 3 1.8k
Daniel M Hoefner United States 12 676 0.9× 512 1.5× 309 1.0× 60 0.3× 224 1.3× 21 1.1k

Countries citing papers authored by Peter H. Jones

Since Specialization
Citations

This map shows the geographic impact of Peter H. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter H. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter H. Jones more than expected).

Fields of papers citing papers by Peter H. Jones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter H. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter H. Jones. The network helps show where Peter H. Jones may publish in the future.

Co-authorship network of co-authors of Peter H. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Peter H. Jones. A scholar is included among the top collaborators of Peter H. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter H. Jones. Peter H. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Jacobson, Terry A., Peter H. Jones, Ralph La Forge, et al.. (2019). The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. Journal of clinical lipidology. 13(3). 415–424. 35 indexed citations
2.
Wilson, Don P., Terry A. Jacobson, Peter H. Jones, et al.. (2019). Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of clinical lipidology. 13(3). 374–392. 339 indexed citations breakdown →
3.
Jacobson, Terry A., Matthew K. Ito, Kevin C. Maki, et al.. (2014). National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary. Journal of clinical lipidology. 8(5). 473–488. 364 indexed citations breakdown →
4.
Jones, Peter H., Radhika Nair, & Kamlesh M. Thakker. (2012). Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin‐Treated Subjects From 3 Data Sources: A Retrospective Analysis. Journal of the American Heart Association. 1(6). e001800–e001800. 98 indexed citations
5.
Wu, Huaizhu, Xiaoyuan Dai Perrard, Qun Wang, et al.. (2009). CD11c Expression in Adipose Tissue and Blood and Its Role in Diet-Induced Obesity. Arteriosclerosis Thrombosis and Vascular Biology. 30(2). 186–192. 122 indexed citations
6.
Polsani, Venkateshwar, Peter H. Jones, Christie M. Ballantyne, & Vijay Nambi. (2008). A case report of myopathy from consumption of red yeast rice. Journal of clinical lipidology. 2(1). 60–62. 16 indexed citations
7.
Bays, Harold & Peter H. Jones. (2007). Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. SHILAP Revista de lepidopterología. 3 indexed citations
8.
Plana, Juan Carlos & Peter H. Jones. (2001). The use of statins in acute coronary syndromes: The mechanisms behind the outcomes. Current Atherosclerosis Reports. 3(5). 355–364. 22 indexed citations
9.
Jones, Peter H.. (2000). Diet and pharmacologic therapy of obesity to modify atherosclerosis. Current Atherosclerosis Reports. 2(4). 314–320. 5 indexed citations
10.
Jones, Peter H.. (1998). Future of lipid-lowering trials: what else do we need to know?. The American Journal of Cardiology. 82(6). 32M–38M. 2 indexed citations
11.
Ballantyne, Christie M., J. Alan Herd, J. Kay Dunn, et al.. (1997). Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Current Opinion in Lipidology. 8(6). 354–361. 40 indexed citations
12.
Jones, Peter H.. (1994). Low serum cholesterol increases the risk of noncardiovascular events: An antagonist viewpoint. Cardiovascular Drugs and Therapy. 8(6). 871–874. 2 indexed citations
13.
Jones, Peter H., et al.. (1994). Clinical Pharmacokinetics of Pravastatin. Clinical Pharmacokinetics. 27(2). 94–103. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Colquhoun Breakdown of academic impact, for papers by J.J.P. Kastelein Breakdown of academic impact, for papers by Antonio J. Vallejo‐Vaz Breakdown of academic impact, for papers by David Neff Breakdown of academic impact, for papers by Michael Stepanavage Breakdown of academic impact, for papers by José Luis Zamorano Breakdown of academic impact, for papers by Brad Bisson Breakdown of academic impact, for papers by Anja Vogt Breakdown of academic impact, for papers by Greg Brown Breakdown of academic impact, for papers by Daniel M Hoefner
Rankless by CCL
2026